Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections

Ocular bacterial infections can lead to serious visual disability without proper treatment. Moxifloxacin (MOX) has been approved by the US Food and Drug Administration as a monotherapy for ocular bacterial infections and is available commercially as an ophthalmic solution (0.5% w/v). However, precor...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef, Ahmed Adel Ali, Thakkar, Ruchi, Senapati, Samir, Joshi, Poorva H., Dudhipala, Narendar, Majumdar, Soumyajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228176/
https://www.ncbi.nlm.nih.gov/pubmed/35745818
http://dx.doi.org/10.3390/pharmaceutics14061246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228176/
https://www.ncbi.nlm.nih.gov/pubmed/35745818
http://dx.doi.org/10.3390/pharmaceutics14061246

Ejemplares similares